HAYWARD, Calif., Feb. 23, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it will hold a conference call to discuss the analytical method of the upcoming VISTA-16 interim biomarker analysis and the expected timeline of the results.
Conference Call Access:
February 28, 2011
5:00 pm Eastern Time
To access the 24-hour audio replay, U.S. and Canadian participants may dial (800) 642-1687; international participants may dial (706) 645-9291. The conference ID for the replay is 45608522. The audio replay will be available until March 7, 2011. This conference call will be webcast live and archived on Anthera's website until February 28, 2012, www.anthera.com.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease (CAD). Anthera's Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulator (BAFF) which has been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus
erythematosus, or lupus. For more information, please visit www.anthera.com.
CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., email@example.com or 510-856-5586.
SOURCE Anthera Pharmaceuticals, Inc.